Sling raises $123M to test oral thyroid eye disease drug in phase 3
The funding will push an oral rival to the infused treatment Tepezza through late-stage trials and toward market entry.
Sling Therapeutics has secured $123 million in a series C financing round, according to a company announcement covered by Fierce Biotech. The proceeds are earmarked to carry its experimental oral medication for thyroid eye disease through a phase 3 clinical trial and, if successful, toward commercialization.
The therapy is designed as a direct competitor to Tepezza, an infused treatment for the same condition. Because Sling's candidate is taken orally, it could offer patients a less burdensome dosing option compared with intravenous infusions, though the source does not provide comparative efficacy or safety data.
The funding round represents a significant vote of confidence in the program, but the source notes no specific timeline for trial results or regulatory submission. All details in this article derive solely from the Fierce Biotech report.
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.